ASSET ACQUISITION (Details) - Asset Acquisition Of Oratech Pharmaceuticals Ltd [Member] - Share Purchase Agreement [Member] $ in Thousands |
1 Months Ended |
|---|---|
|
Mar. 25, 2026
USD ($)
| |
| Asset Acquisition [Line Items] | |
| Cash acquired | $ 6,500 |
| Prepaid clinical trial services asset | 975 |
| In-process research and development (“IPR&D”) | 4,947 |
| Total | $ 12,422 |
| X | ||||||||||
- Definition Asset Acquisition Consideration Transferred In process research and development No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|